Guillain-Barré Syndrome

The most pertinent curriculum item for perioperative care is "...the principles of anaesthesia for patients with... Guillain-Barré".

There is also reference to the critical care side of things in knowing the "Management of the patient with neurological deterioration including... Guillain-Barré".

An SAQ in 2018 (56.9% pass rate) saw marks lost on the correct definition of GBS and the correct use of muscle relaxants in these patients.

In a 2022 CRQ (66.1% pass rate) marks were lost by describing the general intra-operative management of a critically ill patient, rather than the measures specific to a patient recovering from GBS.

Resources


  • Guillain-Barré syndrome (GBS) is a heterogeneous, immune-mediated disease of the peripheral nerves, usually triggered by a preceding infection
  • It typically presents as an acute, rapidly progressive, symmetrical, flaccid and areflexic weakness, starting in the legs

  • Affects ~150,000 people worldwide each year
  • Risk increases with age and is higher in men
  • 20-30% develop respiratory failure requiring mechanical ventilation

Preceding infection

  • Two-thirds report a respiratory or gastrointestinal infection in the 4-6 weeks before neurological symptoms
  • A specific organism is identified serologically in ~50% of these

  • Campylobacter jejuni
    • The most common cause (~30% of patients)
    • Associated with axonal, more severe disease and a worse prognosis

  • Mycoplasma pneumoniae is the most common preceding infection in children

  • Others include:
    • CMV, EBV and hepatitis E
    • Influenza A and B
    • HIV; can occur at any stage, mostly in those not yet immunocompromised
    • Zika virus outbreaks
    • COVID-19; an association exists but a causal link has not been shown

Other triggers

  • Vaccination; remains controversial
    • Seasonal influenza vaccine: negligible increase in risk
    • Recombinant herpes zoster vaccine and viral vector COVID-19 vaccines: slight increase in risk
    • mRNA COVID-19 vaccines: no increased risk

  • Surgery and trauma, particularly spinal surgery and in patients with active malignancy
  • Drugs e.g. TNF-α antagonists and immune checkpoint inhibitors, although whether this represents true GBS is uncertain

  • The immune response to the preceding infection produces antibodies that cross-react with peripheral nerve components; this is known as molecular mimicry
  • Only proven for C. jejuni and M. pneumoniae

  • C. jejuni lipo-oligosaccharides resemble peripheral nerve gangliosides, leading to anti-ganglioside antibodies:
    • Anti-GM1; motor forms of GBS
    • Anti-GQ1b; Miller Fisher syndrome
  • M. pneumoniae produces antibodies against galactocerebroside

  • The result is myelin destruction ± axonal damage, typically at the nodes of Ranvier

  • GBS can be classified into forms and variants on clinical grounds
  • There is considerable overlap and patients rarely show all features of a given variant
  • Electrophysiologically, disease can be demyelinating (AIDP; acute inflammatory demyelinating polyradiculoneuropathy) or axonal (AMAN and AMSAN; acute motor ± sensory axonal neuropathy)

Form or variant Frequency Features
Motor-sensory 30-85% Most common form in Europe and North America with symmetrical weakness and paraesthesiae in upper and lower limbs
Pure motor 5-25% Most common form in Asia with symmetrical weakness without sensory signs
Miller Fisher syndrome 5-25% Triad of ophthalmoplegia, ataxia and areflexia
Anti-GQ1b antibodies
May progress to limb weakness (overlap syndrome)
Paraparetic 5-10% Motor and sensory symptoms confined initially to the legs
Pharyngeal-cervical-brachial <5% Weakness initially of pharyngeal, neck and arm muscles
Bilateral facial palsy <5% Bilateral facial weakness with paraesthesiae
Bickerstaff brainstem encephalitis <5% As Miller Fisher, plus impaired consciousness and pyramidal tract signs
Pure sensory <1% Sensory neuropathy without weakness


Neurological

  • Rapidly progressive, symmetrical weakness, usually starting in the legs and ascending to the arms and cranial nerves
  • Flaccid paresis with absent or reduced reflexes in affected limbs
  • Sensory signs often mild, although most report paraesthesiae in the hands and feet

  • Pain affects two-thirds in the acute phase
    • Mainly back and limbs
    • May precede the onset of weakness

  • Cranial nerve involvement in up to 50%
    • Bilateral facial palsy most common
    • Oculomotor and oropharyngeal (bulbar) weakness also common
    • Neck flexor weakness is often marked

  • Time course:
    • Progression usually lasts <2 weeks
    • Nadir is reached within 4 weeks in >95%

Respiratory

  • Up to 30% require invasive ventilation
  • Deterioration is often rapid:
    • Median of 4 days from onset of weakness to ventilation
    • 82% of those needing ventilation do so within a week of hospital admission
  • Median duration of ventilation ~20 days; outcome is worse if ventilated >14 days

Cardiovascular

  • Autonomic dysfunction occurs in ~40%
    • Arrhythmias, including bradyarrhythmias and heart block
    • Wide swings in blood pressure
    • Exaggerated responses to stimuli e.g. tracheal suctioning, which can precipitate cardiac arrest
  • More likely with quadriparesis, bulbar and neck flexor weakness and in ventilated patients
  • Associated with more complications, worse functional outcome and higher mortality

Gastrointestinal

  • Ileus (autonomic)
  • Dysphagia and aspiration risk with bulbar weakness

Renal

  • Urinary retention (autonomic)
  • Hyponatraemia from SIADH

Bloods

  • FBC, glucose, U&E and LFTs in all patients, mainly to exclude alternative diagnoses e.g. electrolyte disturbance, infection, malignancy, vitamin deficiency or toxins
  • Clotting (particularly before plasma exchange)

  • Serology for preceding infection is useful for surveillance but does not change treatment
  • Anti-ganglioside antibodies are not routinely recommended (low-moderate sensitivity, does not guide treatment)
    • The exception is anti-GQ1b, which is found in most patients with Miller Fisher syndrome

CSF analysis

  • Lumbar puncture is recommended in all suspected cases
  • Classically shows raised protein with a normal or only slightly raised white cell count (albuminocytological dissociation)

  • In the first week, CSF protein is normal in up to 50%
  • ~15% have a mild pleocytosis
  • Perform before starting IVIg, which can falsely raise both protein and cell count
  • Repeat LP only if the diagnosis is in doubt

Nerve conduction studies

  • Recommended to increase diagnostic certainty
  • Typically shows a demyelinating or axonal polyradiculoneuropathy
  • May be normal in the first weeks but can be repeated after 2-3 weeks if needed

Imaging

  • MRI only in atypical cases to exclude alternatives e.g. nerve root compression or leptomeningeal malignancy
  • Nerve root enhancement on MRI is sensitive but non-specific

Other

  • ECG to check arrhythmias and ST/T-wave changes from autonomic dysfunction
  • Serial FVC, single breath count, ABG (see below)

  • Patients at risk of needing ventilation should be monitored in critical care so deterioration is recognised early
  • However, early elective ventilation in high-risk patients has not been shown to prevent pneumonia or improve outcome

Risk factors for mechanical ventilation

  • Rapid progression of limb weakness
  • Inability to walk 10m
  • Neck, facial and bulbar weakness
  • Inability to cough
  • Autonomic dysfunction, including arrhythmias

Risk scores

  • Erasmus GBS Respiratory Insufficiency Score (EGRIS) is a validated tool for predicting respiratory failure in the first week of admission
    • A score of 5-7 suggests ~65% probability of respiratory insufficiency

  • Modified EGRIS (mEGRIS) is a simplified version usable up to a month after symptom onset
    • Scores bulbar weakness, days from onset of weakness to admission, neck flexion power and hip flexion power
    • Not yet externally validated

Bedside respiratory assessment

  • Clinical review 3-6 times a day e.g. 4-hourly monitoring if still deteriorating
  • Inability to count from 1 to 20 in a single breath indicates higher risk
  • FVC <20ml/kg or a fall >30% from predicted should prompt critical care review
  • Bedside tests often give false positives due to poor technique and fatigue
  • Hypoxaemia and hypercapnia are late signs so normal blood gases and saturations should not be relied upon

The 20/30/40 rule: anticipating the need for ventilation
Vital capacity <20ml/kg
Maximum inspiratory pressure <30cmH2O
Maximum expiratory pressure <40cmH2O

Respiratory support

  • Intubation is usually required when:
    • FVC reaches 15ml/kg, or
    • ABG suggests impending hypoxaemic (aspiration, atelectasis) or hypercapnic (neuromuscular weakness) respiratory failure
  • Use NIV with caution
    • May worsen dysautonomia
    • Over-reliance risks an unplanned emergency intubation
    • Unsafe with significant bulbar weakness
  • Prone positioning early in deterioration may slow respiratory decline

  • There are two equally effective immunomodulatory therapies: IVIg and plasma exchange (PE)
    • Equivalent functional outcome at 4 weeks when started within 2 weeks of onset of weakness
    • No difference in time to unaided walking or mortality

  • Start as soon as possible in suspected GBS where there is:
    • Inability to walk 10m unaided
    • Rapid deterioration
    • Dysphagia
    • Respiratory failure

  • IVIg is preferred in most centres as it is easier to give and widely available
  • Corticosteroids are of no benefit, either alone or alongside IVIg

IVIg Plasma exchange
Regimen 0.4g/kg daily for 5 days 4-5 exchanges of ~3L (12-15L total)
Access Peripheral Central venous access required
Contraindications Hypersensitivity or previous anaphylaxis to IVIg; IgA deficiency or anti-IgA antibodies Haemodynamic instability (relative); continuous flow machines are better tolerated
Other considerations Falsely raises CSF protein and cell count; thromboembolic risk Albumin replacement ↓ fibrinogen and prothrombin; FFP replacement has more adverse events

Side-effects of IVIg


Constitutional CNS Significant
Nausea Headache Anaphylaxis
Fever Aseptic meningitis Thromboembolism
Malaise Encephalopathy Acute kidney injury
Raised liver enzymes Erythroderma

Poor response to treatment

  • Patients may deteriorate during treatment, but the full course should still be given
  • No response: a second course of IVIg is not indicated; it does not improve outcome and increases thromboembolic risk
  • Treatment-related fluctuation (initial improvement then secondary deterioration): repeat the same therapy
  • Progression after 8 weeks, or ≥3 relapses, suggests acute-onset chronic inflammatory demyelinating polyneuropathy (CIDP), which needs distinct maintenance treatment

Special groups

  • Miller Fisher syndrome
    • Milder course; most recover completely within 6 months without treatment
    • Monitor for progression to overlap syndrome
  • Bickerstaff brainstem encephalitis; more severe, treat with IVIg or PE
  • Children; better prognosis, IVIg first-line with PE if contraindicated or ineffective
  • Pregnancy; both are safe in all trimesters, but IVIg is first-line as PE needs more monitoring

  • GBS follows a protracted course of deterioration, plateau and recovery, requiring MDT input from physiotherapy, OT, psychology, pharmacy, SALT and dietetics
  • Patients with complete paralysis often have intact consciousness and sensation; this should be considered at every bedside encounter

Airway and ventilation

  • Early tracheostomy (within 7 days) is common, although there is no mortality benefit
  • Patients intubated for bulbar weakness rather than respiratory failure often wean quickly once a tracheostomy is placed
  • Tracheostomy also aids feeding, communication and mobilisation

Autonomic dysfunction

  • Bradycardia: anticholinergics; temporary pacing if severe
  • Tachycardia or hypertension: short-acting β-blockers
  • Hypotension: fluids and vasopressors, titrated cautiously due to exaggerated responses

Other measures

  • VTE prophylaxis
  • Glycaemic control with insulin; hyperglycaemia is associated with ICU-acquired weakness and worse outcome
  • Nutrition; NG feeding if bulbar weakness
  • Pressure area care and physiotherapy to prevent contractures
  • Analgesia: regular simple analgesia plus neuropathic agents e.g. gabapentinoids or amitriptyline; wean sedatives and opioids as mobility improves
  • Psychological support and screening for depression and delirium

Complications

  • More than 80% suffer early complications; pneumonia and tracheobronchitis are the most common

Category Examples
Autonomic Malignant arrhythmias, heart block, hypertensive crises, urinary retention, GI dysfunction
Pulmonary Atelectasis, aspiration pneumonitis, pneumothorax, effusion
Infection Hospital/ventilator-acquired pneumonia, UTI, sepsis
Thromboembolic DVT, PE
Metabolic Sodium, potassium and calcium disturbance, dysglycaemia, hypoalbuminaemia
Pain Nociceptive and neuropathic
Psychological Delirium, anxiety, depression, PTSD
Musculoskeletal, eyes and skin Pressure ulcers, contractures, corneal ulceration


  • Mortality 3-5% in Europe and North America
    • Mainly from ventilatory failure and arrhythmias
    • Highest mortality is in the protracted recovery phase, so monitor closely after ICU discharge
  • Recurrence ~5%
  • 80% can walk at 6 months; functional recovery may continue for up to 3 years

  • Prolonged ventilation is associated with a worse prognosis, but GBS is monophasic and self-limiting
  • Most patients ventilated for >2 months will eventually walk and live independently; this should inform any discussions about withdrawal of treatment

Poor prognostic factors

  • Increasing age
  • Preceding diarrhoeal illness (C. jejuni)
  • Severe weakness at nadir
  • Need for, and duration of, mechanical ventilation
  • Dysautonomia
  • The modified Erasmus GBS Outcome Score (mEGOS) uses these factors within 7 days of admission to predict the probability of being unable to walk independently at 6 months

Rehabilitation

  • Often complicated by fatigue, pain and psychological difficulties
  • Graduated, monitored exercise programmes continuing beyond discharge
  • Pain (muscular, arthralgia, neuropathic radicular) may persist for years in a significant minority

Perioperative management of the patient with Guillain-Barré syndrome


History and examination

  • Phase of disease: progressive, plateau or recovery
  • Extent of weakness, documenting any pre-existing neurological deficit
  • Respiratory reserve: cough, bulbar function, ability to protect the airway
  • Autonomic dysfunction: labile blood pressure, arrhythmias, ileus
  • Current treatment, e.g. recent plasma exchange or IVIg

Investigations

  • FBC, U&E (hyponatraemia, potassium), glucose
  • Clotting and fibrinogen if recent plasma exchange
  • ECG
  • FVC and ABG to establish a baseline

Planning

  • Book a critical care bed; post-operative ventilation may be needed
  • Discuss risk of prolonged ventilation and post-operative deterioration with the patient
  • Continue VTE prophylaxis

Monitoring and access

  • AAGBI standard monitoring
  • Arterial line pre-induction due to autonomic instability
  • Quantitative neuromuscular monitoring if NMBA used
  • External pacing pads and atropine available

Induction and airway

  • RSI if bulbar weakness, as risk of aspiration
  • Cautious titration of induction agents; risk of profound hypotension
  • Exaggerated haemodynamic responses to laryngoscopy, suctioning and position change
  • Vasopressors in reduced doses, as there may be an exaggerated response to sympathomimetics

Neuromuscular blockade

  • Suxamethonium is contraindicated
    • Up-regulation of extrajunctional acetylcholine receptors causes hyperkalaemia and cardiac arrest
    • This risk may persist long after neurological recovery
  • Increased sensitivity to non-depolarising NMBAs
    • Avoid where possible
    • If needed, use reduced, titrated doses of rocuronium with quantitative monitoring and full reversal with sugammadex

Regional anaesthesia

  • Neuraxial techniques can be useful to reduce opioid requirements
  • Expect exaggerated hypotension with autonomic dysfunction
  • Document existing deficits beforehand

Other care

  • Careful positioning and pressure area protection
  • Temperature monitoring; thermoregulation may be impaired
  • Lung-protective ventilation

  • Critical care or HDU for monitoring of respiratory function and autonomic instability
  • Low threshold for post-operative ventilation; extubate only once full reversal confirmed and respiratory function adequate
  • Multimodal, opioid-sparing analgesia, including regional techniques and neuropathic agents
  • Serial FVC monitoring
  • VTE prophylaxis, physiotherapy and pressure area care